menu
    • menu
    [{"orgOrder":0,"company":"AcuraStem","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"AS-202","moa":"PIKfyve","graph1":"Neurology","graph2":"Preclinical","graph3":"AcuraStem","amount2":0.57999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.57999999999999996,"dosageForm":"Injection","sponsorNew":"AcuraStem \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"AcuraStem \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AcuraStem","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"AS-202","moa":"PIKfyve","graph1":"Neurology","graph2":"Preclinical","graph3":"AcuraStem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AcuraStem \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"AcuraStem \/ US Department of Defense"}]

    Find Clinical Drug Pipeline Developments & Deals by AcuraStem

    Menu

    AcuraStem

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AcuraStem

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            AcuraStem

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AS-202

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $580.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics

                            Details : Under the terms of the agreement, Takeda will receive an exclusive, worldwide license to AcuraStem's PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 25, 2023

                            Lead Product(s) : AS-202

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $580.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AcuraStem

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            AcuraStem

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AS-202

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : US Department of Defense

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            AcuraStem Awarded $1M DOD Grant to Advance AS-202 Drug Development Candidate for ALS

                            Details : The CDMRP award nomination underscores the significance of AcuraStem’s drug candidate AS-202. AcuraStem’s most advanced therapeutic candidate, AS-202, lowers levels of the lipid kinase PIKFYVE.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 25, 2021

                            Lead Product(s) : AS-202

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : US Department of Defense

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth